Long-Term Outcomes of Different Surgical Techniques for Sacral Tarlov Cysts: A Prospective Cohort Study
Launched by BEIJING JISHUITAN HOSPITAL · Dec 24, 2024
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different surgical techniques can help adults aged 18 to 75 years who have painful sacral Tarlov cysts, which are fluid-filled sacs located near the lower spine. The researchers want to find out if one type of surgery is better than the others for relieving pain and improving everyday activities, as well as how often problems come back or complications arise after surgery. Participants will have one of three surgical options and will be followed for up to two years to see how well they recover.
To be eligible for this study, individuals must be diagnosed with symptomatic sacral Tarlov cysts through MRI and have symptoms like persistent lower back pain, numbness, or issues with bowel, bladder, or sexual function. They should not have had prior surgery for these cysts or other serious health conditions that could complicate the surgery. Participants will be assessed before and after their surgery to track their pain levels and overall recovery. This trial is still in the planning stages and has not yet started recruiting participants.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • 1. Age 18-75 years.
- • 2. Diagnosed with symptomatic sacral Tarlov cysts confirmed by MRI.
- 3. Presence of at least one of the following symptoms:
- • Persistent sacral or lower back pain (VAS score ≥ 4).
- • Neurological deficits such as lower extremity numbness or weakness.
- • Bowel, bladder, or sexual dysfunction attributable to the cyst.
- • 4. Eligible for surgical intervention based on clinical evaluation.
- • 5. Willing and able to provide written informed consent.
- • Exclusion Criteria
- • 1. History of prior sacral Tarlov cyst surgery.
- • 2. Concurrent spinal conditions requiring separate surgical intervention.
- • 3. Active infection or systemic inflammatory disease.
- • 4. Severe comorbidities that increase surgical risk (e.g., advanced cardiac or pulmonary disease).
- • 5. Pregnancy or lactation.
- • 6. Inability to comply with follow-up requirements.
- • 7. Known allergy or contraindication to surgical materials (e.g., fibrin glue).
About Beijing Jishuitan Hospital
Beijing Jishuitan Hospital is a renowned medical institution specializing in orthopedic and trauma care, with a strong emphasis on research and clinical innovation. As a leading clinical trial sponsor, the hospital is dedicated to advancing medical knowledge and improving patient outcomes through rigorous scientific studies. With a team of experienced researchers and healthcare professionals, Beijing Jishuitan Hospital collaborates with various stakeholders to conduct high-quality clinical trials that adhere to ethical standards and regulatory requirements. Its commitment to excellence in patient care and research positions the hospital as a pivotal player in the field of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported